Dec 03, 2020 (Baystreet.ca via COMTEX) -- 2021 could be a big year for this soon-to-be $16-trillion biotech industry.
More importantly, it could be a big year for early investors in this new biotech breakthrough that could effectively treat the world’s #1 disability.
It’s a disability that’s costing the economy $1 trillion in lost production every single year.
In fact, the revolutionary treatment could be at our doorstep by 2021.
In clinical trials it’s successfully treated 80% of patients (see below).
Investors are piling in.
They call this new segment of biotech ‘transformational medicine'…
The next few months are critical.
Why? Global spending on mental healthcare could hit $16 trillion by 2030.
The science may read like the best of Isaac Asimov, but it's very real.
Researchers say it could have huge implications for people with...
- Depression and anxiety
- Bipolar Disorder, OCD and Schizophrenia
- Alzheimer’s and Parkinson’s
- And many other disabling diseases…
And it's all thanks to four naturally occurring “miracle compounds” that help "reset" the human brain...
With the potential to transform the mental health of hundreds of millions starting as early as 2021.
Working in collaboration with the University of Miami...
It already has 5 provisional patents pending on its technology...adding some serious swagger to the IP value here.
And they have more patent applications planned in 2021.
Lobe’s chief scientist, Maghsoud Dariani, with a history of developing medicines through FDA trials, says:
"These four compounds will revolutionize the treatment of mental health disorders. With just one of these compounds alone we're already seeing results in the early trials -- significant decreases in symptoms -- that are off the charts."
Lobe points to a Johns Hopkins study of the efficacy of these classic compounds for treatment of depression and anxiety (a market that could grow to $18.9 billion by 2026) that concluded that psilocybin eased depression and anxiety in patients with life-threatening cancer.
But that was back in 2016. Since then, a collection of new studies have taken this far beyond cancer patients and into the general population suffering from widespread depression, anxiety and PTSD.
Another study from November 2020 found that the compound psilocybin “worked better than the usual antidepressant medications. According to Alan Davis, the author of the study and a faculty member at Johns Hopkins University and Ohio State University, psilocybin’s effect was “more than four times greater”.
The FDA has even called this compound a "Breakthrough Therapy"--for a second time this year.
Nothing resounds louder with investors than that.
Smart investors are paying close attention to this new biotech trend… and they’re preparing to make millions.
THE SMART MONEY IS MOVING IN TO THE #1 OPPORTUNITY FOR INVESTORS IN 2021
Not only is transformational medicine good science...
But it's a tremendous opportunity for investors.
US News & World Report says this could be better than cannabis.
Rolling Stone calls it a “miracle”.
Wildly influential TED Talks is constantly spreading the word.
The Wall Street Journal calls it “fantastic”.
Forbes says the evidence is lining up quickly.
And then there’s the FDA, which--it’s worth repeating--has called it a “breakthrough therapy”.
Tim Ferriss, angel investor extraordinaire and bestselling author of The 4-Hour Workweek, funded Johns Hopkins’ psychedelic research center with over $2 million. Ferriss says this is the world’s proof-of-concept demonstration--the Silicon Valley of psychedelics.
Some of the smartest biotech investors are going all in...
In March 2019, European investors piled into Germany’s ATAI Life Sciences, a psilocybin compound manufacturer, investing more than $40 million in the company and bringing its value up to $240 million.
Brad Loncar, lead biotech investor at Loncar Investments, pinpointed the “ultimate sign for investors” when big pharma got its first approval for a psychedelic-based anti-depressant in the Spring of 2019.
Multi-billionaire and PayPal co-founder Peter Thiel has put big money into this industry.
Billionaire investor Mike Novogratz has also been selling the psychedelic space for years, lauding its massive investment merits.
Big Pharma has seen the writing on the wall. They are going all in, too.
Johnson & Johnson has been pouring money into R&D for years.
When the FDA approved Janssen’s SPRAVATO ketamine-like nasal spray--a J&J company--as an antidepressant in 2019, it was a signal to investors that the hallucinogenic side of biotech was about to explode.
Many are going all in on a $10.6-billion a year niche market for PTSD, depression and anti-anxiety.
And Lobe appears close to a transformational PTSD development, too.
Among four others, it boasts a patent pending for a nasal mist transducer device that aims to offer a transformational approach to PTSD treatment.
Development is already under way and the next news to come out may not just be transformational for PTSD—but for the stock, as well.
LOBE SCIENCES IS FOCUSING ON MULTI-BILLION-DOLLAR PTSD, DEPRESSION AND ANTI-ANXIETY MARKET
The numbers are overwhelming…
The addressable markets for medical access to psychedelics are in the hundreds of millions.
As of 2020, more than 264 million people of all ages suffer from depression, according to the World Health Organization.
Additionally, 1 in 13 people will develop PTSD at some point in their life.
During the global pandemic… 1 in 20 women… and 1 in 50 men were newly diagnosed.
Depression is now the No. 1 cause of disability in the world.
Considering many other mental disorders that psychedelic researchers are working to address, this could be a massive market opportunity.
The functional mushroom market is expected to be worth more than $34 billion by 2024, according to data from Modor Intelligence.
And Lobe Sciences /zigman2/quotes/212735944/delayed CA:LOBE -10.64% /zigman2/quotes/214495817/composite GTSIF -10.05% is working with one of these four "miracle compounds" to reset the brain for PTSD sufferers.
It hopes to become the first treatment a person receives after a traumatic brain event...
To avoid any symptoms of PTSD…
That means no re-experience of trauma, emotional numbness, insomnia, lack of focus, irritability and more.
Current therapies are just 10%-30% effective...